Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Weitere Inhalte

Aktuelle Publikationen

 

Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore). 2021 Jul 16;100(28):e26571.

Rashidi-Alavijeh J, Kahraman A, Gerken G, Theysohn JM, Willuweit K, Hoyer DP, Lange CM, Buechter M. Enzymatic liver function measured by LiMAx is superior to current standard methods in predicting transplant-free survival after TIPS implantation. Sci Rep. 2021 Jul 5;11(1):13834.

Manka P, Sydor S, Wase N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, von Arnim U, Coombes JD, Cubero FJ, Kahraman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G, Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones, and metabolic status. Liver Int. 2021 Jul 5. doi: 10.1111/liv.15003. Online ahead of print.

Buitrago-Molina LE, Dywicki J, Noyan F, Schepergerdes L, Pietrek J, Lieber M, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Anti-CD20 therapy alters the protein signature in experimental murine AIH, but not exclusively towards regeneration. Cells 2021 Jun 11, 10, 1471.

Paternostro R, Staufer K, Traussnigg S, Stättermayer AF, Halilbasic E, Keritam O, Meyer EL, Stift J, Wrba F, Sipos B, Canbay A, Schlattjan M, Aigner E, Datz C, Stickel F, Schafmayer C, Hampe J, Buch S, Prager G, Munda P, Mandorfer M, Ferenci P, Trauner M. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatol Int. 2021 Jun 2. doi: 10.1007/s12072-021-10200-y. Online ahead of print.

Luo X, Zhang R, Lu M, Liu S, Baba HA, Gerken G, Wedemeyer H, Broering R. Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection. Front Immunol. 2021 May 25;12:684424.

Figge A, Sydor S, Wenning C, Manka P, Assmuth S, Vilchez-Vargas R, Link A, Jähnert A, Brodesser S, Lucas C, Nevzorova YA, Faber KN, Moshage H, Porsch-Özcürümez M, Gerken G, Cubero FJ, Canbay A, Bechmann LP. Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults. Clin Nutr. 2021 Apr 20;40(5):2609-2619. doi: 10.1016/j.clnu.2021.04.008. Online ahead of print.

Best J, Gerken G. The narrow ridge from liver damage to hepatocarcino-genesis. Hepatoma Res. 2021;7:32.

Bojkova D, Westhaus S, Costa R, Timmer L, Funkenberg N, Korencak M, Streeck H, Vondran F, Broering R, Heinrichs S, Lang KS, Ciesek S. Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. Cells. 2020 Apr 17;9(4):1003.

Du Y, Anastasiou OE, Strunz B, Scheuten J, Bremer B, Kraft A, Kleinsimglinhaus K, Todt D, Broering R, Hardtke-Wolenski M, Wu J, Yang D, Dittmer U, Lu M, Cornberg M, Björkström NK, Khera T, Wedemeyer H. The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B infection. Liver Int. 2021 Apr 1. doi: 10.1111/liv.14885. Online ahead of print.

Ringe KI, Vo Chieu VD, Wacker F, Lenzen H, Manns MP, Hundt C, Schmidt B, Winther HB. Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. Eur Radiol. 2021 Apr;31(4):2482-2489.

Hupa-Breier KL, Dywicki J, Hartleben B, Wellhöner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. Biomedicines. 2021 Mar 30;9(4):353.

Adamczyk A, Pastille E, Kehrmann J, Vu VP, Geffers R, Wasmer MH, Kasper S, Schuler M, Lange CM, Muggli B, Rau TT, Klein D, Hansen W, Krebs P, Buer J, Westendorf AM. GPR15 facilitates recruitment of regulatory T cells to promote colorectal cancer. Cancer Res. 2021 Mar 16:canres.2133.2020. doi: 10.1158/0008-5472.CAN-20-2133. Online ahead of print.

Tegtmeyer B, Vieyres G, Todt D, Lauber C, Ginkel C, Engelmann M, Herrmann M, Pfaller CK, Vondran FWR, Broering R, Vafadarnejad E, Saliba AE, Puff C, Baumgärtner W, Miskey C, Ivics Z, Steinmann E, Pietschmann T, Brown RJP. Initial HCV infection of adult hepatocytes triggers a temporally structured transcriptional program containing diverse pro- and anti-viral elements. J Virol. 2021 Mar 3:JVI.00245-21. doi: 10.1128/JVI.00245-21. Online ahead of print.

Simon KG, Serfert Y, Buggisch P, Mauss S, Boeker KHW, Klinker H, Müller T, Merle U, Hüppe D, Manns MP, Wedemeyer H. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]. Z Gastroenterol. 2021 Mar;59(3):241-249.

Aregay A, Engel B, Port K, Vondran FWR, Bremer B, Niehaus C, Khera T, Richter N, Jaeckel E, Cornberg M, Taubert R, Wedemeyer H. Distinct Immune imprints of post-Liver transplantation hepatitis C persist despite viral clearance. Liver Transpl. 2021 Jun;27(6):887-899.

Markova A, Wedemeyer H. [Statin use in patients with liver disease - overview and results from a retrospektive observational study]. MMW Fortschr Med. 2021 Feb;163(3):74-77.

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, ..., Buitrago-Molina LE, ..., Sluimer JC, Stallings CL, Tong CK. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021 Feb 8:1-382. doi: 10.1080/15548627.2020.1797280. Online ahead of print.

Du Y, Yan H, Zou S, Khera T, Li J, Han M, Yang X, Wang B, Liu J, Sun S, Zheng X, Dittmer U, Lu M, Yang D, Wedemeyer H, Wu J. Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T-Cell Responses in a Mouse Model. Hepatol Commun. 2021 Feb 5;5(5):865-881.

Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 Feb 3. doi: 10.1038/s41416-021-01260-w. Online ahead of print.

Du Y, Yang X, Li J, Sokolova V, Zou S, Han M, Yan H, Wey K, Lu M, Dittmer U, Yang D, Epple M, Wu J. Delivery of Toll-Like Receptor 3 Ligand Poly(I:C) to the Liver by Calcium Phosphate Nanoparticles Conjugated with an F4/80 Antibody Exerts an Anti-Hepatitis B Virus Effect in a Mouse Model. Acta Biomater. 2021 Feb 1:S1742-7061(21)00073-8. doi: 10.1016/j.actbio.2021.01.045. Online ahead of print.

Markova AA, Deterding K, Port K, Bantel H, Manns MP, Cornberg M, Wedemeyer HLiver stiffness across different chronic liver disease under therapy with statin in a real life cohort. Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):223-229.

Buitrago-Molina LE, Pietrek J, Noyan F, Schlue J, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun. 2021 Feb;117:102591.

Anastasiou OE, Yurdaydin C, Maasoumy B, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Liebig S, Bantel H, Bremer B, Manns MP, Cornberg M, Wedemeyer H. A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. J Viral Hepat. 2021 Feb;28(2):410-419.

Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver Int. 2021 Feb;41(2):295-299.

Khera T, Du Y, Todt D, Deterding K, Strunz B, Hardtke S, Aregay A, Port K, Hardtke-Wolenski M, Steinmann E, Björkström NK, Manns MP, Hengst J, Cornberg M, Wedemeyer H; HepNet Acute HCV IV Study Group. Long-lasting Imprint in the Soluble Inflammatory Milieu despite Early Treatment of Acute Symptomatic Hepatitis C. J Infect Dis. 2021 Jan 31:jiab048. doi: 10.1093/infdis/jiab048. Online ahead of print.

Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. [68Ga]Ga-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC). J Nucl Med. 2021 Jan 28:jnumed.120.257915. doi: 10.2967/jnumed.120.257915. Online ahead of print.

Rueschenbaum S, Ciesek S, Queck A, Widera M, Schwarzkopf K, Brüne B, Welsch C, Wedemeyer H, Zeuzem S, Weigert A, Lange CM. Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. Front Immunol. 2021 Jan 26;11:534731.

Gliga S, Fiedler M, Dornieden T, Achterfeld A, Paul A, Horn PA, Herzer K, Lindemann M. Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients. Vaccines (Basel). 2021 Jan 25;9(2):88.

Rueschenbaum S, Cai C, Schmidt M, Schwarzkopf K, Dittmer U, Zeuzem S, Welsch C, Lange CM. Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity. Front Immunol. 2021 Jan 14;11:581352.

Dauth N, Mücke VT, Mücke MM, Lange CM, Welker M, Zeuzem S, Badenhoop K. Hypopituitarism in Wilson's disease resolved after copper-chelating therapy. Endocrinol Diabetes Metab Case Rep. 2021 Jan 11;2021:EDM200086. doi: 10.1530/EDM-20-0086. Online ahead of print.

Buitrago-Molina LE, Dywicki J, Noyan F, Trippler M, Pietrek J, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. Biomedicines. 2021 Jan 9;9(1):E58.

Zhou L, He R, Fang P, Li M, Yu H, Wang Q, Yu Y, Wang F, Zhang Y, Chen A, Peng N, Lin Y, Zhang R, Trilling M, Broering R, Lu M, Zhu Y, Liu S. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun. 2021 Jan 4;12(1):98.

Anastasiou OE, Lange CM. Response to the Letter: Impact of SARS-CoV-2 Infection on Patients Suffering from Liver Injury. Dig Dis. 2021;39(1):68-69.

Anastasiou OE, Korth J, Herbstreit F, Witzke O, Lange CM. Mild versus Severe Liver Injury in SARS-CoV-2 Infection. Dig Dis. 2021;39(1):52-57.

 

Willuweit K, Frey A, Hörster A, Saner F, Herzer K. Real-World Administration of Once-Daily MeltDose® Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation. J Clin Med. 2020 Dec 31;10(1):124.

Rashidi-Alavijeh J, Crämer JC, Sauter HL, Willuweit K, Straub K, Wedemeyer H, Herzer K. Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant. Transpl Infect Dis. 2020 Dec 26:e13553. doi: 10.1111/tid.13553. Online ahead of print.

Sekyere SO, Port K, Deterding K, Cornberg M, Wedemeyer H. Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. United European Gastroenterol J. 2020 Dec 21:2050640620976991. doi: 10.1177/2050640620976991. Online ahead of print.

Manka P, Canbay A, Bechmann LP. Model for end-stage liver disease-sodium in acute-on-chronic liver failure. J Hepatol. 2020 Dec;73(6):1578-1579.

Kasper S, Meiler J, Knipp H, Höhler T, Reimer P, Steinmetz T, Berger W, Linden G, Reis H, Markus P, Paul A, Dechêne A, Schumacher B, Kostbade K, Virchow I, Ting S, Worm K, Schmid KW, Herold T, Wiesweg M, Schuler M, Trarbach T. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial. Clin Colorectal Cancer. 2020 Dec;19(4):236-247.e6.

Wranke A, Hardtke S, Heidrich B, Dalekos G, Yalçin K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. J Viral Hepat. 2020 Dec;27(12):1359-1368.

Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, de Knegt RJ, Hansen BE, Janssen HLA, de Man RA, Feld JJ, van der Meer AJ. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2020 Nov 23:S0168-8278(20)33805-8. doi: 10.1016/j.jhep.2020.11.021. Online ahead of print.

Rashidi-Alavijeh J, Straub K, Achterfeld A, Wedemeyer H, Willuweit K, Herzer K. Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. Transpl Infect Dis. 2020 Nov 20:e13522. doi: 10.1111/tid.13522. Online ahead of print.

Schultz Moreira AR, Rüschenbaum S, Schefczyk S, Hendgen-Cotta U, Rassaf T, Broering R, Hardtke-Wolenski M, Buitrago-Molina LE. 9-PAHSA Prevents Mitochondrial Dysfunction and Increases the Viability of Steatotic Hepatocytes. Int J Mol Sci. 2020 Nov 5;21(21):8279.

Herzer K, Sterneck M, Welker MW, Nadalin S, Kirchner G, Braun F, Malessa C, Herber A, Pratschke J, Weiss KH, Jaeckel E, Tacke F. Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany. J Clin Med. 2020 Nov 5;9(11):3570.

Brown RJP, Tegtmeyer B, Sheldon J, Khera T, ..., Rice CM, Pietschmann T. Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice. Sci Adv. 2020 Nov 4;6(45):eabd3233. doi: 10.1126/sciadv.abd3233.

Wang X, Lin Y, Liu S, Zhu Y, Lu K, Broering R, Lu M. O-GlcNAcylation modulates HBV replication through regulating cellular autophagy at multiple levels. FASEB J. 2020 Nov;34(11):14473-14489.

Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S. Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Adv Ther. 2020 Nov;37(11):4755-4756.

Mücke MM, Rüschenbaum S, Mayer A, Mücke VT, Schwarzkopf KM, Zeuzem S, Kehrmann J, Scholtysik R, Lange CM. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathog. 2020 Oct 30;12(1):51.

Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol. 2020 Oct 8;11:571166.

Schwertheim S, Kälsch J, Jastrow H, Schaefer CM, Theurer S, Ting S, Canbay A, Wedemeyer H, Schmid KW, Baba HA. Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. Sci Rep. 2020 Oct 6;10(1):16533.

Dultz G, Shimakami T, Schneider M, Murai K, Yamane D, Marion A, Zeitler TM, Stross C, Grimm C, Richter RM, Bäumer K, Yi M, Biondi RM, Zeuzem S, Tampé R, Antes I, Lange CM, Welsch C. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors. J Biol Chem. 2020 Oct 2;295(40):13862-13874.

Schwarzkopf KM, Eberle L, Uschner FE, Klein S, Schierwagen R, Mücke MM, Schaefer L, Clària J, Zeuzem S, Hintermann E, Christen U, Lange CM, Trebicka J, Welsch C. Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling? J Hepatol. 2020 Oct;73(4):980-982.

Dietz J, Kalinina OV, Vermehren J, Peiffer KH, Matschenz K, Buggisch P, Niederau C, Schattenberg JM, Müllhaupt B, Yerly S, Ringelhan M, Schmid RM, Antoni C, Müller T, Schulze Zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg CP, Zeuzem S, Welsch C, Sarrazin C; European HCV Resistance Study Group. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. J Viral Hepat. 2020 Oct;27(10):974-986.

Kamal H, Westman G, Falconer K, Duberg AS, Weiland O, Haverinen S, Wejstål R, Carlsson T, Kampmann C, Larsson S, Björkman P, Nystedt A, Cardell K, Svensson S, Stenmark S, Wedemeyer H, Aleman S. Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020 Oct;72(4):1177-1190.

Manka P, Syn WK. NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease. Dig Dis Sci. 2020 Sep 26. doi: 10.1007/s10620-020-06620-9. Online ahead of print.

Zhang Z, Trippler M, Real CI, Werner M, Luo X, Schefczyk S, Kemper T, Anastasiou OE, Ladiges Y, Treckmann J, Paul A, Baba HA, Allweiss L, Dandri M, Gerken G, Wedemeyer H, Schlaak JF, Lu M, Broering R. Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes. Hepatology. 2020 Sep;72(3):829-844.

Kinast V, Plociennikowska A, Anggakusuma, Bracht T, Todt D, Brown RJP, Boldanova T, Zhang Y, Brüggemann Y, Friesland M, Engelmann M, Vieyres G, Broering R, Vondran FWR, Heim MH, Sitek B, Bartenschlager R, Pietschmann T, Steinmann E. C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. J Hepatol. 2020 Sep;73(3):549-558.

Sydor S, Manka P, van Buren L, Theurer S, Schwertheim S, Best J, Heegsma J, Saeed A, Vetter D, Schlattjan M, Dittrich A, Fiel MI, Baba HA, Dechêne A, Cubero FJ, Gerken G, Canbay A, Moshage H, Friedman SL, Faber KN, Bechmann LP. Hepatocyte KLF6 expression affects FXR signalling and the clinical course of primary sclerosing cholangitis. Liver Int. 2020 Sep;40(9):2172-2181.

Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, Bondin M, Zhang Z, Marra F, Belperio PS, Wedemeyer H, Flamm S. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. Adv Ther. 2020 Sep;37(9):4033-4042.

Haubold J, Reinboldt MP, Wetter A, Li Y, Ludwig JM, Lange C, Wedemeyer H, Schotten C, Umutlu L, Theysohn J. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. Rofo. 2020 Sep;192(9):862-869.

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Heneghan MA, Drenth JPH. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver Int. 2020 Sep;40(9):2164-2171.

Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon KG, Teuber G, Deterding K, Schulze Zur Wiesch J, Jung MC, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Z Gastroenterol. 2020 Sep;58(9):841-846.

Willuweit K, Frey A, Bieniek L, Heinold A, Büchter M, Horn PA, Wedemeyer H, Herzer K. HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. BMC Gastroenterol. 2020 Aug 27;20(1):288.

Teufel M, Schweda A, Dörrie N, Musche V, Hetkamp M, Weismüller B, Lenzen H, Stettner M, Kohler H, Bäuerle A, Skoda EM. Not all world leaders use Twitter in response to the COVID-19 pandemic: impact of the way of Angela Merkel on psychological distress, behaviour and risk perception. J Public Health (Oxf). 2020 Aug 18;42(3):644-646.

Mücke VT, Maria Schwarzkopf K, Thomas D, Mücke MM, Rüschenbaum S, Trebicka J, Pfeilschifter J, Zeuzem S, Lange CM, Grammatikos G. Serum Sphingosine-1-Phosphate Is Decreased in Patients With Acute-on-Chronic Liver Failure and Predicts Early Mortality. Hepatol Commun. 2020 Aug 12;4(10):1477-1486.

Yu H, Li M, He R, Fang P, Wang Q, Yu Y, Wang F, Zhou L, Zhang Y, Chen A, Peng N, Liu D, Trilling M, Broering R, Wiemer EAC, Lu M, Zhu Y, Liu S. Major Vault Protein promotes hepatocellular carcinoma via targeting Interferon Regulatory Factor 2 and decreasing p53 activity. Hepatology. 2020 Aug;72(2):518-534.

Mücke MM, Mücke VT, Graf C, Schwarzkopf KM, Ferstl PG, Fernandez J, Zeuzem S, Trebicka J, Lange CM, Herrmann E. Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2020 Aug;11(8):e00223.

Thodou V, Bremer B, Anastasiou OE, Cornberg M, Maasoumy B, Wedemeyer H. Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. J Clin Virol. 2020 Aug;129:104525.

Mangia A, Milligan S, Khalili M, ..., Wedemeyer H, ..., Vanstraelen K, Turnes J. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020 Aug;40(8):1841-1852.

Ringe KI, Bergquist A, Lenzen H, Kartalis N, Manns MP, Wacker F, Grigoriadis A. Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). Eur J Radiol. 2020 Aug;129:109101.

Rashidi-Alavijeh J, Ceylan AS, Wedemeyer H, Kleefisch M, Willuweit K, Lange CM. Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis. PLoS One. 2020 Jul 28;15(7):e0236528.

Manka P, Baba HA, Wedemeyer H, Kahraman A. Diet-refractory NASH in an elderly woman. Gut. 2020 Jul 21:gutjnl-2020-320740. doi: 10.1136/gutjnl-2020-320740. Online ahead of print.

Queck A, Fink AF, Sirait-Fischer E, Rüschenbaum S, Thomas D, Snodgrass RG, Geisslinger G, Baba HA, Trebicka J, Zeuzem S, Weigert A, Lange CM, Brüne B. Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis. Front Immunol. 2020 Jul 14;11:1447.

Gabriel MM, Kircheis G, Hardtke S, Markwardt D, Buggisch P, Mix H, Grüngreiff K, Welzel TM, Kälsch J, Hartmann H, Gerbes AL, Karpowitz MV, Seeliger B, Wedemeyer H, Weissenborn K; HepNet HE-Register Study Group. Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. Eur J Gastroenterol Hepatol. 2020 Jul 8. doi: 10.1097/MEG.0000000000001822. Online ahead of print.

Broering R, Luo X, Liu J, Lu M. Controversial: Early Innate Responses to Hepatitis B Virus Infection, an Explanation for Viral Persistence? Virol Sin. 2020 Jul 6. doi: 10.1007/s12250-020-00235-0. Online ahead of print.

Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, Postel N, Friedrich-Rust M, Hofmann WP; German Hepatitis C-Registry. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C (HCV) infection receiving direct acting antiviral therapy- results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat. 2020 Jul;27(7):690-698.

Alves Vasconcelos MP, DallÁcqua DV, Wedemeyer H, Witkin SS, Mendes-Corrêa MC, Villalobos-Salcedo JM. Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. Am J Trop Med Hyg. 2020 Jul;103(1):169-174.

Weismüller TJ, Zhou T, Kalthoff S, Lenzen H, Manns MP, Strassburg CP. Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. Liver Int. 2020 Jul;40(7):1645-1654.

Meister P, Steinke-Ramming C, Beste M, Lenzen H, Gerken G, Canbay A, Jochum C. CTLA-4 Expression Plays a Role in PSC and PBC Progression. Diseases. 2020 Jun 12;8(2):21.

Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Drenth JPH, Heneghan MA. Rapid Response to Treatment of Autoimmune Hepatitis Associated with Remission at 6 and 12 Months. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1609-1617.e4.

Lampertico P, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020 Jun;72(6):1112-1121.

Schotten C, Wedemeyer H, Best J. Reply to the Letter to the Editor: "Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma". Liver Cancer. 2020 Jun;9(3):363-364.

Maasoumy B, Geretti AM, Frontzek A, Austin H, Aretzweiler G, Garcia-Álvarez M, Leuchter S, Simon CO, Marins EG, Canchola JA, Cornberg M, Delgado R, Wedemeyer H. HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. Hepatol Commun. 2020 May 26;4(7):983-997. 

Römermann D, Ansari N, Schultz-Moreira AR, Michael A, Marhenke S, Hardtke-Wolenski M, Longerich T, Manns MP, Wedemeyer H, Vogel A, Buitrago-Molina LE. Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. Liver Int. 2020 May;40(5):1225-1238.

Mücke MM, Mayer A, Kessel J, Mücke VT, Bon D, Schwarzkopf K, Rüschenbaum S, Queck A, Göttig S, Vermehren A, Weiler N, Welker MW, Reinheimer C, Hogardt M, Vermehren J, Herrmann E, Kempf VAJ, Zeuzem S, Lange CM. Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. Clin Infect Dis. 2020 Apr 15;70(9):1916-1924.

Bothou C, Rüschenbaum S, Kubesch A, Quenstedt L, Schwarzkopf K, Welsch C, Zeuzem S, Welzel TM, Lange CM. Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis. J Clin Med. 2020 Apr 26;9(5):1263.

Schmitt A, Günther R, Mauss S, Boeker KHW, Buggisch P, Hillenbrand H, John C, Klinker H, Pathil A, Simon KG, Serfert Y, Niederau C, Vermehren J, Wedemeyer H, Sarrazin C. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). Z Gastroenterol. 2020 Apr;58(4):341-351.

Gundling F, Rathmayer M, Koller L, Wilke M, Kircheis G, Wedemeyer H, Labenz J, Albert J, Schepp W, Lerch MM; für die DRG-Projektgruppe der DGVS. [Prognostic significance and economic burden of hepatic encephalopathy in liver cirrhosis in German hospitals based on G-DRG data]. Z Gastroenterol. 2020 Apr;58(4):323-331.

David P, Drabczyk-Pluta M, Pastille E, Knuschke T, Werner T, Honke N, Megger DA, Akhmetzyanova I, Shaabani N, Eyking-Singer A, Cario E, Kershaw O, Gruber AD, Tenbusch M, Dietze KK, Trilling M, Liu J, Schadendorf D, Streeck H, Lang KS, Xie Y, Zimmer L, Sitek B, Paschen A, Westendorf AM, Dittmer U, Zelinskyy G. Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. PLoS Pathog. 2020 Mar 30;16(3):e1008340.

Hoyer DP, Benkö T, Manka P, von Horn C, Treckmann JW, Paul A, Minor T. Long-term Outcomes After Controlled Oxygenated Rewarming of Human Livers Before Transplantation. Transplant Direct. 2020 Mar 13;6(4):e542.

Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020 Mar;18(3):728-735.e4.

Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, Lucas C, Wegehaupt A, Wenning C, Aßmuth S, Hohenester S, Link A, Faber KN, Moshage H, Cubero FJ, Friedman SL, Gerken G, Trauner M, Canbay A, Bechmann LP. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clin Transl Gastroenterol. 2020 Mar;11(3):e00131.

Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Estivill Mercade G, Kho D, Petoumenos K, Marks P, Tatsch F, Gabriela Pires Dos Santos A, Gane E; SMART-C Study Group. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020 Mar;72(3):431-440.

Scharf AC, Gronewold J, Dahlmann C, Schlitzer J, Kribben A, Gerken G, Frohnhofen H, Dodel R, Hermann DM. Clinical and functional patient characteristics predict medical needs in older patients at risk of functional decline. BMC Geriatr. 2020 Feb 21;20(1):75.

Anastasiou OE, Thodou V, Berger A, Wedemeyer H, Ciesek S. Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. Pathogens. 2020 Feb 19;9(2):137.

Binh MT, Hoan NX, Giang DP, Tong HV, Bock CT, Wedemeyer H, Toan NL, Bang MH, Kremsner PG, Meyer CG, Song LH, Velavan TP. Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma. Sci Rep. 2020 Feb 18;10(1):2797.

Buechter M, Kahraman A. Predictive value of spleen stiffness in hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2020 Feb;9(1):101-102.

Hadem J, Rossnick R, Hesse B, Herr M, Hansen M, Bergmann A, Kensah G, Maess C, Baraki H, Kümpers P, Lukasz A, Kutschka I. Endothelial dysfunction following coronary artery bypass grafting : Influence of patient and procedural factors. Herz. 2020 Feb;45(1):86-94.

Goetz M, Andersen P, Bergman J, Frei N, Schmidt A, Kähler G, Martus P, Dechêne A. ERCP in babies: Low risk of post-ERCP pancreatitis - results from a multicentre survey. United European Gastroenterol J. 2020 Feb;8(1):77-80.

Wang X, Lin Y, Kemper T, Chen J, Yuan Z, Liu S, Zhu Y, Bröring R, Lu M. AMPK and Akt/mTOR signaling pathways participate in glucose-mediated regulation of HBV replication and cellular autophagy. Cell Microbiol. 2020 Feb;22(2):e13131

Dywicki J, Buitrago-Molina LE, Pietrek J, Lieber M, Broering R, Khera T, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Autoimmune hepatitis induction can occur in the liver. Liver Int. 2020 Feb;40(2):377-381.

Haubold J, Ludwig JM, Li Y, Buechter M, Wetter A, Umutlu L, Theysohn JM. Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization. PLoS One. 2020 Jan 29;15(1):e0227972.

Ebel F, Deterding K, Port K, Schlevogt B, Manns MP, Maasoumy B, Cornberg M, Wedemeyer H. Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. Aliment Pharmacol Ther. 2020 Jan;51(1):194-195.

 

Schwertheim S, Theurer S, Jastrow H, Herold T, Ting S, Westerwick D, Bertram S, Schaefer CM, Kälsch J, Baba HA, Schmid KW. New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation. PLoS One. 2019 Dec 16;14(12):e0226199. doi: 10.1371/journal.pone.0226199.

Zhang R, Lin H, Broering R, Shi D, Yu X, Xu L, Wu W, Liu C. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway. Signal Transduct Target Ther. 2019 Dec 6;4:54. doi: 10.1038/s41392-019-0082-5.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Dec 14;394(10215):2184-2196.

Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Hüppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J. Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. J Clin Med. 2019 Dec 2;8(12). pii: E2101. doi: 10.3390/jcm8122101.

Schotten C, Bechmann LP, Manka P, Theysohn J, Dechêne A, El Fouly A, Barbato F, Neumann U, Radünz S, Sydor S, Heider D, Venerito M, Canbay A, Gerken G, Herrmann K, Wedemeyer H, Best J. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer. 2019 Nov;8(6):491-504.

Kleefisch M, Lange C, Wedemeyer H. Betablocker helfen bei Leberzirrhose. MMW Fortschr Med. 2019 Nov;161(20):39. Review. German

Mücke MM, Maasoumy B, Dietz J, Mücke VT, Simon CO, Canchola JA, Cornberg M, Marins EG, Manns MP, Zeuzem S, Wedemeyer H, Sarrazin C, Vermehren J. Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. PLoS One. 2019 Nov 18;14(11):e0224751.

Queck A, Thomas D, Jansen C, Schreiber Y, Rüschenbaum S, Praktiknjo M, Schwarzkopf KM, Mücke MM, Schierwagen R, Uschner FE, Meyer C, Clària J, Zeuzem S, Geisslinger G, Trebicka J, Lange CM. Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS One. 2019 Oct 23;14(10):e0222840. doi: 10.1371/journal.pone.0222840.

Kleinert RDV, Montoya-Diaz E, Khera T, Welsch K, Tegtmeyer B, Hoehl S, Ciesek S, Brown RJP. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. Viruses. 2019 Oct 17;11(10). pii: E960. doi: 10.3390/v11100960. Review.

Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, Li Y, Manns MP, Lengauer T, Wedemeyer H, Kraft ARM, Falk CS, Cornberg M. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci Rep. 2019 Oct 1;9(1):14118.

Deterding K, Wedemeyer H. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. AIDS Rev. 2019;21(3):126-134.

Friebus-Kardash J, Gäckler A, Kribben A, Witzke O, Wedemeyer H, Treckmann J, Herzer K, Eisenberger U. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. Transpl Infect Dis. 2019 Oct;21(5):e13146.

Soon CF, Behrendt P, Todt D, Manns MP, Wedemeyer H, Chen MS, Cornberg M. Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E. J Hepatol. 2019 Oct;71(4):673-684.

Dehnen D, Herwig A, Herzer K, Weltermann B. Improving the Vaccination Status of Liver Transplant Patients: Effectiveness of Personally Addressing Patients and Written Recommendations to Family Physicians after 3 Years. Transpl Infect Dis. 2019 Oct;21(5):e13140.

Beer A, Holzmann H, Pischke S, Behrendt P, Wrba F, Schlue J, Drebber U, Neudert B, Halilbasic E, Kreipe H, Lohse A, Sterneck M, Wedemeyer H, Manns M, Dienes HP. Chronic Hepatitis E is associated with Cholangitis. Liver Int. 2019 Oct;39(10):1876-1883.

Stahl K, Hadem J, Schneider A, Manns MP, Wiesner O, Schmidt BMW, Hoeper MM, Busch M, David S. Therapeutic plasma exchange in acute liver failure. J Clin Apher. 2019 Oct;34(5):589-597.

Jeschke B, Gottlieb A, Sowa JP, Jeschke S, Treckmann JW, Gerken G, Canbay A. Single-Center Retrospective Study of Clinical and Laboratory Features That Predict Survival of Patients With Budd-Chiari Syndrome After Liver Transplant. Exp Clin Transplant. 2019 Oct;17(5):665-672.

Jahn M, Rekowski J, Gerken G, Kribben A, Canbay A, Katsounas A. The predictive performance of SAPS 2 and SAPS 3 in an intermediate care unit for internal medicine at a German university transplant center; A retrospective analysis. PLoS One. 2019 Sep 25;14(9):e0222164. doi: 10.1371/journal.pone.0222164.

Buechter M, Kersting S, Gerken G, Kahraman A. Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease. Sci Rep. 2019 Sep 19;9(1):13577.

Anastasiou OE, Theissen M, Verheyen J, Bleekmann B, Wedemeyer H, Widera M, Ciesek S. Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. Viruses. 2019 Sep 16;11(9). pii: E863. doi: 10.3390/v11090863.

Eyking A, Ferber F, Köhler S, Reis H, Cario E. TRIM58 Restrains Intestinal Mucosal Inflammation by Negatively Regulating TLR2 in Myeloid Cells. J Immunol. 2019 Sep 15;203(6):1636-1649.

Soon CF, Zhang S, Suneetha PV, Antunes DA, Manns MP, Raha S, Schultze-Florey C, Prinz I, Wedemeyer H, Sällberg Chen M, Cornberg M. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. Front Immunol. 2019 Sep 4;10:2076. doi: 10.3389/fimmu.2019.02076.

Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, Frenzel A, Hust M, Galla M, Buitrago-Molina LE, Manns MP, Jaeckel E, Hardtke-Wolenski M. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019 Sep;103:102289.

Scharf AC, Gronewold J, Dahlmann C, Schlitzer J, Kribben A, Gerken G, Rassaf T, Kleinschnitz C, Dodel R, Frohnhofen H, Hermann DM. Health outcome of older hospitalized patients in internal medicine environments evaluated by Identification of Seniors at Risk (ISAR) screening and geriatric assessment. BMC Geriatr. 2019 Aug 14;19(1):221.

Manka P, Bechmann L, Best J, Sydor S, Claridge LC, Coombes JD, Canbay A, Moeller L, Gerken G, Wedemeyer H, Syn WK. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. Dig Dis Sci. 2019 Aug;64(8):2351-2358.

Dias J, Hengst J, Parrot T, Leeansyah E, Lunemann S, Malone DFG, Hardtke S, Strauss O, Zimmer CL, Berglin L, Schirdewahn T, Ciesek S, Marquardt N, von Hahn T, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Sandberg JK, Björkström NK. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. J Hepatol. 2019 Aug;71(2):301-312.

Sandmann L, Dörge P, Wranke A, Vermehren J, Welzel TM, Berg CP, Grottenthaler JM, Weiss KH, Langel J, Sterneck M, von Wulffen M, Manns MP, Wedemeyer H, Hardtke S, von Hahn T. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. Eur J Gastroenterol Hepatol. 2019 Aug;31(8):1049-1056.

Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol. 2019 Aug;54(8):1033-1041.

Husen P, Straub K, Willuweit K, Hagemann A, Wedemeyer H, Bachmann HS, Herzer K. SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. Transplant Proc. 2019 Jul - Aug;51(6):1962-1971.

Aregay A, Sekyere SO, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H. Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. J Hepatol. 2019 Nov;71(5):889-899.

Lange CM. Systemic inflammation in hepatorenal syndrome - A target for novel treatment strategies? Liver Int. 2019 Jul;39(7):1199-1201.

Jüngst C, Gräber S, Simons S, Wedemeyer H, Lammert F. Medication Adherence among Patients with Chronic Diseases: a Survey Based Study in Pharmacies. QJM. 2019 Jul 1;112(7):505-512.

Bedreli S, Straub K, Achterfeld A, Willuweit K, Katsounas A, Saner F, Wedemeyer H, Herzer K. The effect of immunosuppression on coagulation after liver transplant. Liver Transpl. 2019 Jul;25(7):1054-1065.

Straub K, Husen P, Baba HA, Trippler M, Wedemeyer H, Herzer K. Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. Cancer Med. 2019 Jul;8(8):3793-3802.

Meister P, Dechêne A, Büchter M, Kälsch J, Gerken G, Canbay A, Jochum C. Spleen Stiffness Differentiates Between Acute and Chronic Liver Damage and Predicts Hepatic Decompensation. J Clin Gastroenterol. 2019 Jul;53(6):457-463.

Schwertheim S, Westerwick D, Jastrow H, Theurer S, Schaefer CM, Kälsch J, Möllmann D, Schlattjan M, Wedemeyer H, Schmid KW, Baba HA. Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival. J Pathol Clin Res. 2019 Jul;5(3):164-176.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut. 2019 Jun;68(6):1099-1107.

Domouchtsidou A, Barsegian V, Mueller SP, Lobachevsky P, Best J, Horn PA, Bockisch A, Lindemann M. DNA lesions correlate with lymphocyte function after selective internal radiotherapy. Cancer Immunol Immunother. 2019 Jun;68(6):907-915.

Manka P, Zeller A, Syn WK. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs. 2019 Jun;79(9):903-927.

Husen P, Hornung J, Benko T, Klein C, Willuweit K, Buechter M, Saner FH, Paul A, Treckmann JW, Hoyer DP. Risk Factors for High Mortality on the Liver Transplant Waiting List in Times of Organ Shortage: A Single-Center Analysis. Ann Transplant. 2019 May 3;24:242-251.

Karimzadeh H, Kiraithe MM, Oberhardt V, Alizei ES, Bockmann J, Zur Wiesch JS, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C. Mutations in Hepatitis D Virus Allow it to Escape Detection by CD8+ T Cells and Evolve at the Population Level. Gastroenterology. 2019 May; 156(6): 1820-1833.

Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN). Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol. 2019 May; 70(5): 1008-1015.

Hadem J, Kielstein JT, Manns MP, Kümpers P, Lukasz A. Outcomes of renal dysfunction in patients with acute liver failure. United European Gastroenterol J. 2019 Apr;7(3):388-396.

Wiesweg M, Kasper S, Worm K, Herold T, Reis H, Sara L, Metzenmacher M, Abendroth A, Darwiche K, Aigner C, Wedemeyer HH, Helfritz FA, Stuschke M, Schumacher B, Markus P, Paul A, Rahmann S, Schmid KW, Schuler M. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. Oncogene. 2019 Apr;38(16):2953-2966.

Dirks M, Haag K, Pflugrad H, Tryc AB, Schuppner R, Wedemeyer H, Potthoff A, Tillmann HL, Sandorski K, Worthmann H, Ding X, Weissenborn K. Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. J Viral Hepat. 2019 Apr;26(4):422-431.

Hengst J, Klein AL, Lunemann S, Deterding K, Hardtke S, Falk CS, Manns MP, Cornberg M, Schlaphoff V, Wedemeyer H. Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. J Viral Hepat. 2019 Apr;26(4):466-475.

Jebran AF, Schmidt WE, Kahraman A, Canbay A, Bulut K. Sarcoidosis of the Intra- and Extrahepatic Bile Ducts with Concomitant Cholangitis in a Patient with Ulcerative Colitis. Case Rep Gastroenterol. 2019 Mar 29;13(1):153-158.

Christensen S, Buggisch P, Mauss S, Böker KH, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H; German Hepatitis C-Registry. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). Subst Abuse. 2019 Mar 28;13:1178221819835847. doi: 10.1177/1178221819835847. eCollection 2019.

Canbay A, Kälsch J, Neumann U, Rau M, Hohenester S, Baba HA, Rust C, Geier A, Heider D, Sowa JP. Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective. PLoS One. 2019 Mar 26;14(3):e0214436. doi: 10.1371/journal.pone.0214436. eCollection 2019.

Pavlovic V, Yang L, Chan HL, Hou J, Janssen HL, Kao JH, Lampertico P, Peng CY, Piratvisuth T, Thompson AJ, Wedemeyer H, Wei L, Wat C. Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. Antivir Ther. 2019; 24(2):133-140.

Buechter M, Gerken G, Kahraman A. Immunoglobulin G4-Related Pancreatitis: Our Experience in a German Cohort of 59 Patients. Pancreas. 2019 Mar;48(3):e17-e19. doi: 10.1097/MPA.0000000000001264. No abstract available.

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019 Mar;19(3):275-286

Anastasiou OE, Widera M, Westhaus S, Timmer L, Korth J, Gerken G, Canbay A, Todt D, Steinmann E, Schwarz T, Timm J, Verheyen J, Ciesek S. Clinical outcome and viral genome variability of hepatitis B virus induced acute liver failure. Hepatology. 2019 Mar;69(3):993-1003.

Ringe KI, Grigoriadis A, Halibasic E, Wacker F, Manns MP, Schramm C, Lenzen H; MRI working group of the IPSCSG. Recommendations on the use of magnetic resonance imaging for collaborative multicenter studies in PSC. Hepatology. 2019 Mar;69(3):1358-1359.

Wedemeyer H, Negro F. Devil hepatitis D: an orphan disease or largely underdiagnosed? Gut. 2019 Mar;68(3):381-382.

Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer. 2019 Feb;8(1):41-65.

Abendroth A, Noureddine R, Abramczyk M, Paul A, Gerken G, Schmid KW, Markus P, Schumacher B, Wiesweg M, Köhler J, Markus M, Mende B, Dechêne A, Schuler M, Kasper S. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. J Cancer Res Clin Oncol. 2019 Feb;145(2):445-455.

Pischke S, Peron JM, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse AW, Wedemeyer H, de Man R, Mallet V. Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. Viruses. 2019 Feb 22;11(2). pii: E186. doi: 10.3390/v11020186.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.

Wedemeyer H. The widespread rarity of HBsAg loss in chronic hepatitis B. Lancet Gastroenterol Hepatol. 2019 Mar;4(3):190-192.

Willuweit K, Bezinover D, Herzer K, Nowak KM, Paul A, Saner FH. Efficacy of IgM-enriched Immunoglobulin for Vasopressor-resistant Vasoplegic Shock After Liver Transplantation. Transplantation. 2019 Feb;103(2):381-386.

Schwarzkopf KM, Queck A, Thomas D, Angioni C, Cai C, Freygang Y, Rüschenbaum S, Geisslinger G, Zeuzem S, Welsch C, Lange CM. Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation. PLoS One. 2019 Jan 31;14(1):e0211537.

Roggendorf H, Krawczyk A, Lindemann M, Shouval D, Michler T, Roggendorf M, Gerken G. Induction of Functional Control in Chronic Hepatitis B Patients with Low Level HBsAg Using a Combination of a PreS1/S2/S HBV Vaccine (Sci-BVacTM) and a Nucleoside Analogue. J Infect Dis Ther 2019 Jan 29; 7(1):390.

Schwarzkopf K, Rüschenbaum S, Barat S, Cai C, Mücke MM, Fitting D, Weigert A, Brüne B, Zeuzem S, Welsch C, Lange CM. IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute-on-Chronic Liver Failure. Hepatol Commun. 2019 Jan 17;3(3):392-405.

Hüppe D, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H. [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. Z Gastroenterol. 2019 Jan;57(1):27-36.

Schütte A, Ciesek S, Wedemeyer H, Lange CM. Influenza virus infection as precipitating event of acute-on-chronic liver failure. J Hepatol. 2019 Apr; 70(4): 797-799.

Tischendorf M, Fuchs A, Zeuzem S, Lange CM. Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events. J Hepatol. 2019 Apr;70(4):800-801.

Attia D, Deterding K, Cornberg J, Gebel MJ, Cornberg M, Manns MP, Wedemeyer H, Potthoff A. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. Eur J Gastroenterol Hepatol. 2019 Jan;31(1):67-74.

Zoubek ME, Woitok MM, Sydor S, Nelson LJ, Bechmann LP, Lucena MI, Andrade RJ, Bast A, Koek GH, Trautwein C, Cubero FJ. Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofen-induced acute liver injury. J Pathol. 2019 Jan;247(1):110-122.

Buechter M, Thimm J, Baba HA, Bertram S, Willuweit K, Gerken G, Kahraman A. Liver Maximum Capacity: A Novel Test to Accurately Diagnose Different Stages of Liver Fibrosis. Digestion. 2019;100(1):45-54.

Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2019;24(2):117-123.

Gottlieb A, Kottmann M, Manka P, Bedreli S, Hadem J, Bechmann L, Sowa JP, Gerken G, Canbay A. How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis. Dig Dis. 2019;37(2):147-154.

Eisenberger U, Friebus-Kardash J, Guberina H, Kribben A, Witzke O, Willuweit K, Gerken G, Herzer K. Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. Transplant Direct. 2018 Dec 27;5(1):e419. doi: 10.1097/TXD.0000000000000860. eCollection 2019 Jan.

Taubert R, Diestelhorst J, Junge N, Kirstein MM, Pischke S, Vogel A, Bantel H, Baumann U, Manns MP, Wedemeyer H, Jaeckel E. Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. Sci Rep. 2018 Nov 28;8(1):17452. doi: 10.1038/s41598-018-35882-7.

Beckebaum S, Herzer K, Bauhofer A, Gelson W, De Simone P, de Man R, Engelmann C, Müllhaupt B, Vionnet J, Salizzoni M, Volpes R, Ercolani G, De Carlis L, Angeli P, Burra P, Dufour JF, Rossi M, Cillo U, Neumann U, Fischer L, Niemann G, Toti L, Tisone G. Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. Ann Transplant. 2018 Nov 13;23:789-801.

Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, Zimmermann T, Manns MP, Sarrazin C, Hüppe D, Wedemeyer H, Vermehren J. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int. 2018 Nov;38(11):1906-1910.

Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, Hatzakis A. The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. J Viral Hepat. 2018 Nov;25 Suppl 3:6-14.

Pietsch V, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. United European Gastroenterol J. 2018 Oct;6(8):1188-1198.

Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg CP, Welker MW, Pischke S, Sterneck M, Mehrabi A, Weiss KH, Herber A, Berg T, Zimmermann T, Galle PR, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns MP, Zeuzem S, Wedemeyer H. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. J Hepatol. 2018 Oct;69(4):982-984.

Saleh M, Welsch C, Cai C, Döring C, Gouttenoire J, Friedrich J, Haselow K, Sarrazin C, Badenhoop K, Moradpour D, Zeuzem S, Rueschenbaum S, Lange CM. Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. J Steroid Biochem Mol Biol. 2018 Oct;183:142-151.

Queck A, Rueschenbaum S, Kubesch A, Cai C, Zeuzem S, Weigert A, Brüne B, Nour-Eldin NA, Gruber-Rouh T, Vogl T, Lange CM. The portal vein as a distinct immunological compartment - A comprehensive immune phenotyping study. Hum Immunol. 2018 Oct;79(10):716-723.

van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky JM, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer H, Feld JJ. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864.

Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M. Contrasting Timing of Virological Relapse after Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-negative Patients. J Infect Dis. 2018 Sep 22;218(9):1480-1484.

Dultz G, Müller T, Petersen J, Mauss S, Zimmermann T, Muche M, Simon KG, Berg T, Zeuzem S, Hüppe D, Böker K, Wedemeyer H, Welzel TM; Leberstiftungs-GmbH Deutschland. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs Aging. 2018 Sep;35(9):843-857.

Shetty A, Hsu JW, Manka PP, Syn WK. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2018 Dec; 63(12): 3187-3206.

Wedemeyer H. E-xchange: Hepatitis E and the risk of plasma products for organ transplant recipients. Transplantation 2018 Aug;102(8):1209-1210.

Kraef C, Schlein C, Hiller J, Westhölter D, Denzer U, Horvatits T, Peine S, Lohse AW, Lütgehetmann M, Polywka S, Pischke S. Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. J Clin Virol. 2018 Aug;105:26-30.

Lange CM, Bechstein WO, Berg T, Engelmann C, Bruns T, Canbay A, Moreau R, Trebicka J. Acute-on-Chronic Liver Failure. Visc Med. 2018 Aug;34(4):296-300.

Wedemeyer H. Supplement: Perspektiven der Infektiologie. Deutsches Hepatitis C-Register: Aktuelle Auswertungen und ihre Konsequenzen. Dtsch Arztebl 2018; 115(27-28): [4]; DOI: 10.3238/PersInfek.2018.07.09.001

Du K, Liu J, Broering R, Zhang X, Yang D, Dittmer U, Lu M. Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opin Drug Discov. 2018 Jul;13(7):661-670.

Strunz B, Hengst J, Wedemeyer H, Björkström NK. Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity. Cell Stress. 2018 Jul 25;2(8):216-218.

Sarrazin C, Zimmermann T, Berg T, Neumann UP, Schirmacher P, Schmidt H, Spengler U, Timm J, Wedemeyer H, Wirth S, Zeuzem S; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Pathologie e.V. (DGP); Deutsche Leberstiftung; Gesellschaft für Virologie e.V. (GfV); Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE); Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH); Schweizerische Gesellschaft für Gastroenterologie (SGG); Deutsche Transplantationsgesellschaft e.V. (DTG); Deutsche Leberhilfe e.V; Deutsche Gesellschaft für Infektiologie e.V. (DGI); Deutsche Gesellschaft für Suchtmedizin e.V. (DGS); Deutsche AIDS-Gesellschaft e.V. (DAIG); Deutsche Arbeitsgemeinschaft niedergelassener Ärzte für die Versorgung HIV-Infizierter (DAGNÄ); Robert Koch-Institut. [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. Z Gastroenterol. 2018 Jul;56(7):756-838.

Buechter M, Gerken G, Hoyer DP, Bertram S, Theysohn JM, Thodou V, Kahraman A. Liver maximum capacity (LiMAx) test as a helpful prognostic tool in acute liver failure with sepsis: a case report. BMC Anesthesiol. 2018 Jun 20;18(1):71.

Strunz B, Hengst J, Deterding K, Manns MP, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK. Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. Nat Commun. 2018 Jun 11;9(1):2275.

Lutterkort GL, Wranke A, Hengst J, Yurdaydin C, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Manns MP, Dienes HP, Falk C, Wedemeyer H, Heidrich B. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. J Viral Hepat. 2018 Nov;25(11):1384-1394.

Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M, Seeger F, Schoelzel F, Martinez Y, Zeuzem S, Bojunga J, Lange CM. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun. 2018 Jun 6;2(7):798-806.

Juntermanns B, Kaiser GM, Orth L, Reis H, Jaradat D, Sydor S, Buechter M, Kasper S, Mathé Z, Sotiropoulos GC, Baba HA, Canbay A, Paul A, Fingas CD. Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. Eur J Med Res. 2018 Jun 1;23(1):29.

Wiesweg M, Reis H, Köster T, Goetz M, Worm K, Herold T, Paul A, Dechêne A, Schumacher B, Markus P, Virchow I, Kostbade K, Wolf N, Zaun G, Metzenmacher M, Schmid KW, Schuler M, Kasper S. Phosphorylation of p70 Ribosomal Protein S6 Kinase ß-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 Jun;17(2):e331-e352.

Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int. 2018 May;38(5):821-833.

Domouchtsidou A, Barsegian V, Mueller SP, Best J, Ertle J, Bedreli S, Horn PA, Bockisch A, Lindemann M. Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy. Cancer Immunol Immunother. 2018 May;67(5):843-853.

Binh MT, Hoan NX, Van Tong H, Giang DP, Sy BT, Toan NL, Song LH, Bang MH, Wedemeyer H, Meyer CG, Kremsner PG, Bock CT, Velavan TP. HDV infection rates in northern Vietnam. Sci Rep. 2018 May 23;8(1):8047.

Canbay A, Müller MN, Philippou S, Gerken G, Tromm A. Cholesteryl Ester Storage Disease: Fatal Outcome without Causal Therapy in a Female Patient with the Preventable Sequelae of Progressive Liver Disease after Many Years of Mild Symptoms. Am J Case Rep. 2018 May 18;19:577-581.

Aregay A, Dirks M, Schlaphoff V, Sekyere SO, Haag K, Falk CS, Hengst J, Bremer B, Schuppner R, Manns MP, Pflugrad H, Cornberg M, Wedemeyer H, Weissenborn K. Systemic inflammation and immune cell phenotypes are associated with neuro-psychiatric symptoms in patients with chronic inflammatory liver diseases. Liver Int. 2018 Dec;38(12):2317-2328.

Anastasiou OE, Dogan-Cavus B, Kucukoglu O, Baba H, Kahraman A, Gerken G, Schramm C, Canbay A. Corticosteroid Therapy Improves the Outcome of Autoimmune Hepatitis-Induced Acute Liver Failure. Digestion. 2018 Apr 26;98(2):104-111.

Horvatits T, Ozga AK, Westhölter D, Hartl J, Manthey CF, Lütgehetmann M, Rauch G, Kriston L, Lohse AW, Bendall R, Wedemeyer H, Dalton HR, Pischke S. Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. Liver Int. 2018 Nov;38(11):1951-1964.

Fingas CD, Beste M, Penndorf V, Sydor S, Nadalin S, Bechmann L, Paul A, Gerken G, Canbay A, Jochum C. Liver Regeneration-Related Cytokine Profiles in Donors and Recipients Before and After Living-Donor Liver Transplant. Exp Clin Transplant. 2018 Oct;16(5):554-561.

Buechter M, Manka P, Heinemann FM, Lindemann M, Baba HA, Schlattjan M, Canbay A, Gerken G, Kahraman A. Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol. 2018 Apr 7;24(13):1410-1418.

Deterding K, Manns MP, Wedemeyer H. [Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]. Internist (Berl). 2018 Apr;59(4):401-409.

Mettke F, Wedemeyer H. Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis-Authors' reply. Aliment Pharmacol Ther. 2018 Apr;47(8):1231-1232.

Liu J, Yu Q, Wu W, Huang X, Broering R, Werner M, Roggendorf M, Yang D, Lu M. TLR2 Stimulation Strengthens Intrahepatic Myeloid-Derived Cell-Mediated T Cell Tolerance through Inducing Kupffer Cell Expansion and IL-10 Production. J Immunol. 2018 Apr 1;200(7):2341-2351.

Büchter M, Gerken G, Kahraman A. IgG4-Associated Inflammatory Pseudotumor with Bilobar Hepatic Foci. Dtsch Arztebl Int. 2018 Mar 16;115(11):181.

Ravens S, Hengst J, Schlapphoff V, Deterding K, Dhingra A, Schultze-Florey C, Koenecke C, Cornberg M, Wedemeyer H, Prinz I. Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. Front Immunol. 2018 Mar 16;9:510.

Anastasiou OE, Widera M, Korth J, Kefalakes H, Katsounas A, Hilgard G, Gerken G, Canbay A, Ciesek S, Verheyen J. Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. J Med Virol. 2018 Feb;90(2):282-290.

Frey A, Piras-Straub K, Walker A, Timm J, Gerken G, Herzer K. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype. Transpl Infect Dis. 2018 Feb;20(1). doi: 10.1111/tid.12803.

Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Dürig J, Hoffmann D, Küppers R. Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals. Blood. 2018 Feb 1;131(5):546-557.

Mazzolini G, Atorrasagasti C, Onorato A, Peixoto E, Schlattjan M, Sowa JP, Sydor S, Gerken G, Canbay A. SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Sci Rep. 2018 Jan 15;8(1):725. doi: 10.1038/s41598-017-18981-9.

Anastasiou O, Bechmann LP, Canbay A. High ferritin levels are not only but mostly because of liver specific injury. Liver Int. 2018 Jan;38(1):191-192.

Buechter M, Manka P, Theysohn JM, Reinboldt M, Canbay A, Kahraman A. Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. Dig Liver Dis. 2018 Jan;50(1):54-60.